Lifileucel
Phase 2Recruiting 1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Endometrial Cancer
Conditions
Endometrial Cancer
Trial Timeline
Oct 29, 2024 → Nov 1, 2029
NCT ID
NCT06481592About Lifileucel
Lifileucel is a phase 2 stage product being developed by Iovance Biotherapeutics for Endometrial Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06481592. Target conditions include Endometrial Cancer.
What happened to similar drugs?
0 of 20 similar drugs in Endometrial Cancer were approved
Approved (0) Terminated (0) Active (20)
Hype Score Breakdown
Clinical
12
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07288203 | Phase 2 | Recruiting |
| NCT06481592 | Phase 2 | Recruiting |
| NCT02360579 | Phase 2 | Completed |
Competing Products
20 competing products in Endometrial Cancer